

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

29 Jun 2026

### Comparative study of four conservative treatments for patients with knee osteoarthritis

#### Protocol summary

##### Study aim

Determination of therapeutic effect and treatment difference in administration of celecoxib with intravenous injection in patients with osteoarthritis

##### Design

Blocked randomized, Parallel group trial with blinded outcome assessment, Clinical trial with control group

##### Settings and conduct

In this method, patients suffering from knee DJD refer to orthopedic clinic of Hamadan Besat Hospital because of knee pain. First, an experienced person is examined the patients and a radiologic imaging (lateral, AP, rozenberg view) have be done for the patient. Before a patient is injected, a questionnaire is based on VAS sacore and the test and the patient's pain intensity is given and filled. Patients are then re-visited at intervals of three weeks, six weeks, and three months, and their VAS is measured. During this period, the investigator is not aware of the injected drug

##### Participants/Inclusion and exclusion criteria

1. Patients with knee osteoarthritis with grade of 2 and 3
2. Agree to participate in the study
1. osteoarthritis degrees 0, 1, 4
2. Unstable joint
3. Hemorrhagic disorders
4. Knee joint infections in injection site
5. The history of surgery in the last year
6. History of knee infection in the last year
7. Failure to follow the patient

##### Intervention groups

The first group (A) received celecoxib 200 mg twice daily with intradermal injection of placebo. The second group (B) uses the same selcocide distraction with intra-articular injection of a 40-mg depotmedol injection. The third group (C) received celecoxib 200 mg twice daily with an injection of hyaluronic acid (a medicine containing 10 mg in 2.5 cc) The fourth group (D) of celecoxib with the same dose, with injection of depotomeric ampoules, receives hyaluronic acid (combination) ampoules.

##### Main outcome variables

pain

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20190114042360N1**

Registration date: **2019-08-19, 1398/05/28**

Registration timing: **registered\_while\_recruiting**

Last update: **2019-08-19, 1398/05/28**

Update count: **0**

##### Registration date

2019-08-19, 1398/05/28

##### Registrant information

##### Name

Maryam Zamanirafe

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 81 3821 8792

##### Email address

zamanirafe.maryam@gmail.com

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2019-06-22, 1398/04/01

##### Expected recruitment end date

2019-08-20, 1398/05/29

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

##### Scientific title

Comparative study of four conservative treatments for patients with knee osteoarthritis

#### Public title

Study of four conservative treatment of osteoarthritis

#### Purpose

Treatment

#### Inclusion/Exclusion criteria

##### Inclusion criteria:

Patients with knee osteoarthritis grade of 2 and 3 Agree to participate in the study

##### Exclusion criteria:

Osteoarthritis grade 0, 1, 4 Unstable joint Bleeding disorders Joint and pathogenic infection of injection site Surgery history in the last year History of knee infection in the last year Unable to follow the patient

#### Age

No age limit

#### Gender

Both

#### Phase

3

#### Groups that have been masked

- Investigator
- Data analyser

#### Sample size

Target sample size: **120**

#### Randomization (investigator's opinion)

Randomized

#### Randomization description

Patients are randomly assigned to one of four groups: the first group (A) receives 200 mg of celecoxib twice daily with intradermal injection of placebo (distilled water). The second group (B) is the same as the intracellular injection of celecoxib A 40-mm dipomedulum ampoule is used jointly. The third group (C) received celecoxib 200 mg twice daily with an injection of hyaluronic acid (a medicine containing 10 mg in 2.5 cc). The fourth group (D) of celecoxib with the same dose was injected with depotomeric ampoules, hyaluronic acid Combination). The 8th block means that the first patient is treatment A, the second patient treatment C, the patient D treatment, the fourth patient B treatment, the patient the treatment B, the sixth patient D treatment, the seventh patient C treatment, the eighth patient A, and until the end of the work Until all samples are completed.

#### Blinding (investigator's opinion)

Double blinded

#### Blinding description

In this study, the researcher only receives the received code of the injected drug into the knee joint and carries out follow-up follow-up.

#### Placebo

Used

#### Assignment

Parallel

#### Other design features

## Secondary Ids

empty

## Ethics committees

### 1

#### Ethics committee

##### Name of ethics committee

Ethics committee of Hamedan University of Medical Sciences

##### Street address

Hamedan University of Medical Sciences, Park Blvd, Hamadan Town

##### City

Hamedan

##### Province

Hamadan

##### Postal code

6517838698

#### Approval date

2019-04-27, 1398/02/07

#### Ethics committee reference number

IR.UMSHA.REC.1398.036

## Health conditions studied

### 1

#### Description of health condition studied

Osteoarthritis

#### ICD-10 code

#### ICD-10 code description

## Primary outcomes

### 1

#### Description

pain

#### Timepoint

before and 1,3 and 6 weeks after of injection

#### Method of measurement

use of Visual Analogue Scale

## Secondary outcomes

empty

## Intervention groups

### 1

#### Description

Control group: Injection of placebo in the knee

#### Category

Placebo

### 2

#### Description

Intervention group: First intervention group: Injection of Ampule-40, 1 vial of 1 ml of pharmaceutical Exir Company-Iran in knee

**Category**

Treatment - Drugs

**3**

**Description**

Intervention group: Second Intervention group: Injection of Ampule-40, 1 vial of 1 ml of pharmaceutical Exir Company-Iran in knee and Injections of 20 mg 2 ml intrajoint hyaline ampoule made by Fidia Italy

**Category**

Treatment - Drugs

**4**

**Description**

Intervention group: Third intervention group: Injections of 20 mg 2 ml intrajoint hyaline ampoule made by Fidia Italy

**Category**

Treatment - Drugs

**Recruitment centers**

**1**

**Recruitment center**

**Name of recruitment center**

Besat hospital

**Full name of responsible person**

Maryam Zamani Rafe

**Street address**

Besat Hospital, Masqineh Road, Shahid Motahari Boulevard

**City**

Hamedan

**Province**

Hamadan

**Postal code**

6514845411

**Phone**

+98 81 3264 0030

**Fax**

+98 81 3265 1515

**Email**

besat@umsha.ac.ir

**Web page address**

**Sponsors / Funding sources**

**1**

**Sponsor**

**Name of organization / entity**

Hamedan University of Medical Sciences

**Full name of responsible person**

Saeed Bashirian

**Street address**

Hamedan University of Medical Sciences , Facing the

People's Park, Hamedan

**City**

Hamedan

**Province**

Hamadan

**Postal code**

6517838698

**Email**

s\_bashirian@yahoo.com

**Grant name**

**Grant code / Reference number**

**Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Hamedan University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

empty

**Country of origin**

**Type of organization providing the funding**

Academic

**Person responsible for general inquiries**

**Contact**

**Name of organization / entity**

Hamedan University of Medical Sciences

**Full name of responsible person**

Maryam Zamanirafe

**Position**

Intern

**Latest degree**

Medical doctor

**Other areas of specialty/work**

Orthopedics

**Street address**

No. 7;Matin 4 Ave.; Saeedie street.; Hamadan town

**City**

Hamadan

**Province**

Hamadan

**Postal code**

6516956167

**Phone**

+98 81 3821 8792

**Fax**

**Email**

zamanirafe.maryam@gmail.com

**Person responsible for scientific inquiries**

**Contact**

**Name of organization / entity**

Hamedan University of Medical Sciences

**Full name of responsible person**

Maryam Zamanirafe

**Position**

Intern

**Latest degree**

Medical doctor

**Other areas of specialty/work**

Orthopedics

**Street address**

No. 7;Matin 4 Ave.; Saeedie street.; Hamadan town

**City**

Hamadan

**Province**

Hamadan

**Postal code**

6516956167

**Phone**

+98 81 3821 8792

**Fax**

**Email**

zamanirafe.maryam@gmail.com

**Person responsible for updating data**

**Contact**

**Name of organization / entity**

Hamedan University of Medical Sciences

**Full name of responsible person**

Maryam Zamanirafe

**Position**

Intern

**Latest degree**

Medical doctor

**Other areas of specialty/work**

Orthopedics

**Street address**

No. 7;Matin 4 Ave.; Saeedie street.; Hamadan town

**City**

Hamadan

**Province**

Hamadan

**Postal code**

6516956167

**Phone**

+98 81 3821 8792

**Fax**

**Email**

zamanirafe.maryam@gmail.com

**Sharing plan**

**Deidentified Individual Participant Data Set (IPD)**

No - There is not a plan to make this available

**Justification/reason for indecision/not sharing IPD**

No more information

**Study Protocol**

No - There is not a plan to make this available

**Statistical Analysis Plan**

No - There is not a plan to make this available

**Informed Consent Form**

No - There is not a plan to make this available

**Clinical Study Report**

No - There is not a plan to make this available

**Analytic Code**

No - There is not a plan to make this available

**Data Dictionary**

No - There is not a plan to make this available